The cell-free BRAF test for cancer mutation monitoring from Trovagene Inc, San Diego, detects BRAF V600E mutation from cell-free DNA in urine. This mutation commonly occurs in melanoma, as well as several other prevalent cancer types.
Of the more than 70,000 cases of melanoma diagnosed each year in the United States, up to 70% harbor a BRAF-type mutation. Of these, 80% may be positive specifically for BRAF V600E. The ultrasensitive assay procedure monitors this mutation in metastatic cancer patients with biopsy-proven V600E BRAF mutation in their tumor using a noninvasive, systemic sample as an alternative to traditional biopsy methods, which can lead to patient complications and high costs.
For more information, visit Trovagene.
